CN1289593A - Application of oligose mixture in treating stress brain injury - Google Patents
Application of oligose mixture in treating stress brain injury Download PDFInfo
- Publication number
- CN1289593A CN1289593A CN 99120249 CN99120249A CN1289593A CN 1289593 A CN1289593 A CN 1289593A CN 99120249 CN99120249 CN 99120249 CN 99120249 A CN99120249 A CN 99120249A CN 1289593 A CN1289593 A CN 1289593A
- Authority
- CN
- China
- Prior art keywords
- brain injury
- formula
- oligosaccharide mixture
- application
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to the application of oligose mixture in preparing medicine to treat streass brain injury.
Description
The present invention relates to the purposes of oligosaccharide mixture in the anti-stress brain injury derived from the Chinese medicine Radix Morindae Officinalis.
Chinese medicine Radix Morindae Officinalis (mrinda officinalis How) has kidney invigorating and YANG supporting, bone and muscle strengthening, rheumatism effect.Chinese patent application No.94103414.3 has disclosed the medicine that a kind of active component is the anti-psychotic disorder of Radix Morindae Officinalis.Chinese patent application No.94103415.1 has disclosed the formula I oligosaccharide that obtains from Radix Morindae Officinalis extraction and as antipsychotic drug, wherein n=1-8.
But the formula I oligosaccharide yet there are no report in the activity aspect the anti-stress brain injury.
Goal of the invention:
The objective of the invention is to seek the new purposes of formula I oligosaccharide mixture.
The invention summary
The now unexpected after deliberation discovery of the inventor, the oligosaccharide mixture of formula I has good anti-stress brain injury effect.
Therefore, first aspect present invention relates to formula I oligosaccharide mixture and is used for the treatment of purposes in the treating stress brain injury medicine in preparation.
What further aspect of the present invention related to is the method for treatment treating stress brain injury, and it comprises the treating stress brain injury patient who the formula I oligosaccharide mixture of above-mentioned definition is needed treatment.
Describe in detail: the oligosaccharide mixture that the present invention relates to formula I is used for the treatment of the treating stress brain injury medicine in preparation
In purposes, n=1-8 wherein.
The invention still further relates to the method for the sharp brain injury of treatment, it comprises the formula I oligosaccharide
Mixture needs the treating stress brain injury patient of treatment, n=1-8.
According to the present invention, the formula I oligosaccharide mixture of effect of the present invention obtains by extraction plant Radix Morindae Officinalis.Solvent for use is organic solvent, water-containing organic solvent or water in the extraction.Organic solvent is alcohols such as methanol, ethanol, propanol or butanols etc., halo alkanes such as dichloromethane or chloroform etc., esters such as methyl acetate, ethyl acetate, propyl acetate etc., or ethers such as petroleum ether or ether etc.
According to the present invention, formula I oligosaccharide mixture can use separately or with composition forms in being used for the treatment for the treatment of stress brain injury.Administering mode can be oral or parenteral route.Form of administration can be peroral dosage form such as tablet or capsule etc., parenterai administration dosage form such as aseptic injection, drip liquid etc.
The present invention will be described further by the following examples and biological activity test, but this and do not mean that any limitation of the invention.
Embodiment 1
The preparation of formula I oligosaccharide
Get Radix Morindae Officinalis 1KG and pulverized 50 mesh sieves, sieved the thing Petroleum ether extraction.Each with 5 liters of petroleum ether, extract three times.Merge, reduction vaporization is done, and obtains ligroin extraction 100g; The medicinal residues ethanol extraction.Each 8 liters of ethanol of using are carried three times, merge, and reduction vaporization is done, and obtains ethanol extraction 160g.Extract reuse water dissolution filters, and filtered solution distributes extraction in n-butyl alcohol and water, obtain dissolving in the extract 120g and the water-soluble part 300g of n-butyl alcohol.Water-soluble part 100g is separated with the carbon column chromatography, and developing solvent is the ethanol of 10%-70%.Obtain formula I oligosaccharide mixture, heavy 26g (purity almost 100%).Get its part and carry out high pressure liquid chromatography (post: Spherisorb C
18(4.5 * 250mm), detect: RI Waters DifferentialRefractometer 410 (US), pump: Waters
TM600, eluting: 5% methanol-water, flow velocity: 1.0ml/ minute), the retention time that records the formula I oligosaccharide is: the n retention time (minute) 1 2.392 3.053 3.434 4.275 4.536 6.347 7.488 8.47
Biological activity test:
Embodiment 2, formula I oligosaccharide mixture are to the adjusting of corticosterone and testosterone levels in the chronic stress rat serum
1. method and result
The Wistar male rat, body weight 160 ± 20g is divided into 4 groups at random, 8 every group, stress control animals every day shock by electricity, forced swimming, vibration at a high speed, fixing, fasting pessimal stimulations such as (water), time-histories 14 days makes animal be in the chronic stress state.The administration group then stress in lumbar injection (ip) formula I oligosaccharide mixture, normal group is not then accepted any stress stimulation, broken end was got blood and separation of serum in the 15th day, utilized corticosterone, testosterone test kit to measure.The result adds up with one factor analysis of variance.
Table 1. formula I oligosaccharide mixture is to the influence of corticosterone and testosterone levels in the chronic stress rat serum.##P＜0.01, ###P＜0.001 vs normal control, * * P＜0.01, * * * P＜0.001, vs stress contrast, n=8.
2. discuss:
One of key feature of chronic stress is exactly that the corticosterone level significantly raises in the blood, testosterone levels reduces, and two dosage groups of formula I oligosaccharide mixture can reverse this result, and expression can the antagonism chronic stress.
Embodiment 3, formula I oligosaccharide mixture are to the protective effect of the PC12 cell of corticosterone damage
1. method
(contain penicillin sodium 200kUL with the DMEM culture fluid that contains 5% hyclone and 5% horse serum
-1, streptomycin 100mgL
-1, be about 2 * 10 pH7.4) with cell dilution
8.L
- 1Be inoculated in and use poly-D-lysine (0.1g.L in advance
-1) 96 well culture plates handled, every hole 100 μ L put into CO
237 ℃ of incubators (production of U.S. Napco company), 5%CO
2Cultivated under the condition 3～4 days, and treated promptly to can be used for experiment after cell covers with at the bottom of the hole, and reference literature (Liu Jinggen etc., Acta Pharmaceutica Sinica 1998,33 (3): 165) method, improve a little, inhale and remove Cell sap, change and contain respective concentration medicine and 0.2mmol.L
-1Corticosterone (corticosterone, serum-free DMEM Cort) (matched group does not contain any medicine), 37 ℃ of 5%CO
2Cultivated 48 hours, and inhaled and remove culture fluid, wash 2 times with D-Hanks liquid, every hole adds and contains 0.5g.L
-1The serum-free DMEM of MTT cultivates to inhale after 4 hours and removes culture fluid, every hole adds 10% sodium lauryl sulphate, 100 μ L, treat that blue particle dissolves (about 12～16 hours) fully, utilize porous scanning spectrophotometer (model: MCC/340) measure absorbance (A) value of specimen, be used for the quantitative response viable count and calculate the suppression ratio of medicine to the PC12 cell injury of corticosterone damage at 570nm.
Table 2. formula I oligosaccharide mixture is to the protective effect of the PC12 cell of corticosterone damage
| Medicine (mg, ml -1) | Absorbance (A) |
| Normal control corticosterone corticosterone+formula I oligosaccharide mixture 1.25 2.5 5.0 | 1.00±0.05 0.74±0.07 1.14±0.13*** 1.26±0.13*** 1.36±0.06*** |
* * P＜0.001 vs corticosterone damage contrast.
2. result
The PC12 cell is through 0.2mmol.L
-1Corticosterone was handled after 48 hours, to MTT picked-up ability drop, the A value significantly is lower than the normal control group, showing that cell sustains damage or the part cell is in heaven dies, but when formula I oligosaccharide mixture existed, the PC12 cell obviously strengthened MTT picked-up ability, shows that the PC12 cell injury obviously weakens, the living cells showed increased has the concentration dependence.This result shows the damage of the cranial nerve cell that formula I oligosaccharide mixture can cause anti-stress.
Claims (3)
1. formula I oligosaccharide mixture is used for the treatment of purposes in the treating stress brain injury medicine in preparation,
N=1-8 wherein.
2. according to the purposes of claim 1, wherein said medicine can tablet or capsule form use.
3. according to the purposes of claim 1, wherein said medicine can aseptic injection or the use of drip liquid form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB99120249XA CN1141941C (en) | 1999-09-24 | 1999-09-24 | Application of oligose mixture in treating stress brain injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB99120249XA CN1141941C (en) | 1999-09-24 | 1999-09-24 | Application of oligose mixture in treating stress brain injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1289593A true CN1289593A (en) | 2001-04-04 |
| CN1141941C CN1141941C (en) | 2004-03-17 |
Family
ID=5281442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB99120249XA Expired - Fee Related CN1141941C (en) | 1999-09-24 | 1999-09-24 | Application of oligose mixture in treating stress brain injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1141941C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112972483A (en) * | 2021-03-15 | 2021-06-18 | 中国人民解放军军事科学院军事医学研究院 | Application of morinda officinalis oligosaccharide in preparation of medicine for treating body dysfunction caused by altitude anoxia |
-
1999
- 1999-09-24 CN CNB99120249XA patent/CN1141941C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112972483A (en) * | 2021-03-15 | 2021-06-18 | 中国人民解放军军事科学院军事医学研究院 | Application of morinda officinalis oligosaccharide in preparation of medicine for treating body dysfunction caused by altitude anoxia |
| CN112972483B (en) * | 2021-03-15 | 2022-10-28 | 中国人民解放军军事科学院军事医学研究院 | Application of morinda officinalis oligosaccharide in preparation of medicine for treating body dysfunction caused by altitude anoxia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1141941C (en) | 2004-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101297880B (en) | Active extract containing phlorizin and uses thereof | |
| CN101637474B (en) | New application of asperosaponin VI | |
| DE102015120353A1 (en) | Pharmaceutical composition for the support of chemotherapy drugs and their use | |
| CN1203083C (en) | Rhizoma anemarrhenae extract and preparation process and use thereof | |
| CN101781355B (en) | Method for preparing limonin, composition and application thereof | |
| CN110755386A (en) | Application of thesium Chinese granules in preparation of medicine for treating hyperpyrexia caused by pathogenic bacteria infection | |
| CN102935100A (en) | Preparation method and applications of queen lagerstroemia folium apocyni veneti general flavones | |
| CN1141941C (en) | Application of oligose mixture in treating stress brain injury | |
| CN1148193C (en) | Application of oligose treating stress brain injury | |
| CN1857622A (en) | Medicine composition and preparation containing effective components of gastrodia tuber and Chuanxiong rhizome | |
| CN1788758A (en) | Use of traditional Chinese medicine garden burnet and its extract in preparing drug for raising red cell and blood hemoglobin | |
| CN106236792B (en) | The preparation of Folum Ilicis extract and anti-alzheimer's disease purposes | |
| CN1943570A (en) | Use of opc in preparing medicine for treating and preventing senile dementia | |
| CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN1169822C (en) | Quercetin derivative and its medicinal use | |
| CN100343266C (en) | Picrorhiza total glycoside extract and its application in preparation of liver disease medicine and preparation method | |
| CN1081922C (en) | Medicinal composition containing ginsenoside Re, preparation and usage thereof | |
| CN1193766C (en) | Gardenia total glycoside composite for curing hepatitis and its preparation method | |
| CN1453295A (en) | Medicinal polysaccharide component of spinulate hedgehog fungus, its prepn and medicinal composition | |
| CN1887316A (en) | Chinese medicine composition and its prepn process and application | |
| CN1670026A (en) | Lotus plumule alkaloid extract and its preparation process and use in preparation of drugs for cardiovascular and cerebrovascular diseases | |
| CN1369266A (en) | Immunodepressive medicine and its preparing process and application | |
| CN106822205A (en) | Ring conopsea extraction is preparing the application for the treatment of kidney fibrosis medicine and composition | |
| CN1679797A (en) | Anti-cancer Tengli root extract and its making method and use | |
| CN1726952A (en) | Extract product of fenugreek seeds, its extracting method, and treatment diabetes and complication purposes thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1079807 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20040317 Termination date: 20160924 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |